European Commission logo
English English
CORDIS - EU research results
CORDIS

Adaptive Immunity in Human Atherosclerosis: Understanding its Cellular Basis to Define Novel Immunomodulatory Therapies

Project description

Stopping traitors before they turn could provide new therapies for atherosclerosis

Atherosclerosis is a chronic arterial disease characterised by the build-up of lipid-containing materials (plaques) that can clog arteries. Over the last few decades, evidence has shown that immunity-associated chronic inflammation can trigger events leading to severe atherosclerotic cardiovascular disease. Some cells in the immune system recognise a protein in low-density lipoprotein (LDL) cholesterol. It appears that they normally serve a protective function against atherosclerosis but they can become pathogenic during the course of the disease. ANIMATE is looking for evidence of this process using a variety of techniques and systems. Characterising the immune cells' changing functions in time and space could point to novel mechanisms to prevent the protective cell pools from changing their focus.

Objective

Atherosclerosis is a chronic immune disease of arteries that causes vessel-narrowing atherosclerotic plaques. Its acute complications, myocardial infarction and stroke, are the leading causes of death worldwide. Atherosclerosis is accompanied by an inflammatory and autoimmune response with CD4+ T-helper cells that recognize self-antigens, including ApoB-100 (ApoB), the main protein in low-density lipoprotein (LDL) cholesterol. Although their existence has been inferred from indirect evidence, the existence and function of atherosclerosis-specific, self-reactive CD4+ T cells on a single-cell level remains elusive. In particular, it is unclear whether these are pro- or anti-inflammatory.
Preliminary data suggest the existence of a natural pool of ApoB-reactive T-helper cells that share properties with atheroprotective T-regulatory cells but transform into pathogenic T-effector cells in the natural course of disease. This proposal aims to explore this loss of protective immunity on a cellular and function level. It employs novel tools to detect antigen-specific T cells in vivo by MHC-II multimers, mass cytometry (CyTOF), single cell RNA-sequencing (scRNA-seq), lineage-tracing mouse models, and live cell imaging. Based on the anticipated findings, this study will define a map of auto-reactive T-helper cell phenotypes in a temporal, spatial, and functional dimension. These insights will be used to identify novel immunomodulatory strategies to therapeutically stabilize the population of protective ApoB-specific T-helper cells, or to prevent their transformation into pathogenic T cell phenotypes by adoptive cells transfers, vaccination, or cytokine-blockade. In clinical association studies, a direct correlation of auto-immunity and clinical atherosclerosis will be tested.
This proposal will decipher traits of protective immunity in atherosclerosis and help to build the conceptual framework to define novel therapeutic strategies for patients.

Host institution

UNIVERSITAETSKLINIKUM FREIBURG
Net EU contribution
€ 1 499 946,00
Address
HUGSTETTER STRASSE 49
79106 Freiburg
Germany

See on map

Region
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 946,25

Beneficiaries (1)